Paclitaxel-Eluting Balloon vs. Standard Angioplasty to Reduce Recurrent Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: The DEBATE-ISR Study

Purpose To test the ability of a drug-eluting balloon (DEB) to reduce recurrent in-stent restenosis (ISR) in diabetic patients with femoropopliteal stents. Methods A prospective all-comers study [Drug-Eluting Balloon in Peripheral Intervention for In-Stent Restenosis (DEBATE-ISR); ClinicalTrials.gov identifier NCT01558531] of symptomatic diabetic patients with femoropopliteal ISR undergoing treatment with paclitaxel-eluting balloons was designed to compare their 12-month recurrent restenosis rate with that of historical diabetic controls. From January 2010 to December 2011, 44 consecutive diabetic patients (32 men; mean age 74±11 years) were treated with DEBs and enrolled in the study. The control group comprised 42 diabetic patients (23 men; mean age 76±7 years) treated with a conventional balloon for femoropopliteal ISR from 2008 to 2009. Results No significant differences in terms of clinical, angiographic, or procedural characteristics were observed between the study groups. Lesion length was 132±86 mm in the DEB group vs. 137±82 mm in the BA group. Procedural success, defined as a residual stenosis <30% in the restenotic segment (stent +5 mm at proximal and distal edges), was obtained in all treated lesions. At 1-year follow-up, 6 patients died (3 in each group), and 1 patient in the BA group underwent major amputation. Recurrent restenosis, assessed by angiography (66%) or ultrasound (34%), occurred in 8/41 (19.5%) patients in the DEB group vs. 28/39 (71.8%) in the BA group (p<0.001). Target lesion revascularization for symptomatic recurrent restenosis was performed in 6/44 (13.6%) patients in the DEB vs.13/42 (31.0%) in the BA group (p=0.045). Conclusion Using DEB for treating femoropopliteal ISR led to a significant reduction in recurrent restenosis and repeat angioplasty at 1-year follow-up as compared to historical controls.

[1]  I. Porto,et al.  Impact of Critical Limb Ischemia on Long-Term Cardiac Mortality in Diabetic Patients Undergoing Percutaneous Coronary Revascularization , 2013, Diabetes Care.

[2]  P. Fitzgerald,et al.  Duplex criteria for in‐stent restenosis in the superficial femoral artery , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[3]  P. Sidhu,et al.  Randomized Trial of the SMART Stent versus Balloon Angioplasty in Long Superficial Femoral Artery Lesions: The SUPER Study , 2013, CardioVascular and Interventional Radiology.

[4]  L. Dean,et al.  Aneurysm formation after drug‐eluting balloon treatment of drug‐eluting in‐stent restenosis: First case report , 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[5]  B. Cortese,et al.  Paclitaxel coated balloons for coronary artery interventions: a comprehensive review of preclinical and clinical data. , 2012, International journal of cardiology.

[6]  M. Jaff,et al.  Excimer laser with adjunctive balloon angioplasty and heparin-coated self-expanding stent grafts for the treatment of femoropopliteal artery in-stent restenosis: twelve-month results from the SALVAGE study. , 2012, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[7]  E. Stabile,et al.  Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis. , 2012, Journal of the American College of Cardiology.

[8]  A. Kastrati,et al.  Paclitaxel-Coated Versus Uncoated Balloon Angioplasty Reduces Target Lesion Revascularization in Patients With Femoropopliteal Arterial Disease: A Meta-Analysis of Randomized Trials , 2012, Circulation. Cardiovascular interventions.

[9]  M. Buchbinder,et al.  Nitinol Stent Implantation vs. Balloon Angioplasty for Lesions in the Superficial Femoral and Proximal Popliteal Arteries of Patients With Claudication: Three-Year Follow-up From the RESILIENT Randomized Trial , 2012, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[10]  M. Nobuyoshi,et al.  Classification and clinical impact of restenosis after femoropopliteal stenting. , 2012, Journal of the American College of Cardiology.

[11]  J. Laird,et al.  The treatment of femoropopliteal in-stent restenosis: back to the future. , 2012, Journal of the American College of Cardiology.

[12]  J. Laird,et al.  Outcomes following treatment of femoropopliteal in‐stent restenosis: A single center experience , 2011, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[13]  C. Kwolek,et al.  Late outcomes of balloon angioplasty and angioplasty with selective stenting for superficial femoral-popliteal disease are equivalent. , 2011, Journal of vascular surgery.

[14]  M. Dake,et al.  Nitinol Stents With Polymer-Free Paclitaxel Coating for Lesions in the Superficial Femoral and Popliteal Arteries Above the Knee: Twelve-Month Safety and Effectiveness Results From the Zilver PTX Single-Arm Clinical Study , 2011, Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists.

[15]  F. Castriota,et al.  A new paclitaxel-eluting balloon for angioplasty of femoropopliteal obstructions: acute and midterm results. , 2011, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[16]  A. Banning,et al.  Drug-eluting balloons: what is their place on the interventionalist's shelf? , 2010, Heart.

[17]  Pierfrancesco Agostoni,et al.  Quantitative coronary angiography in the current era: principles and applications. , 2009, Journal of interventional cardiology.

[18]  Johannes Lammer,et al.  Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. , 2006, The New England journal of medicine.

[19]  Christopher Piorkowski,et al.  Prevalence and clinical impact of stent fractures after femoropopliteal stenting. , 2005, Journal of the American College of Cardiology.

[20]  J. Lammer,et al.  PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. , 2001, Journal of vascular and interventional radiology : JVIR.